ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (11)
2021
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2019
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
-
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 33, Núm. 12, pp. 2924-2933
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542
2009
-
International prognostic scoring system for Waldenström macroglobulinemia
Blood, Vol. 113, Núm. 18, pp. 4163-4170
2007
-
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
British Journal of Haematology, Vol. 136, Núm. 1, pp. 80-86
2006
-
Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia
Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383